FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast CancerJulia A. Beaver, Patricia Cortazar, Rosane Charlab et al.|Clinical Cancer Research|2015Cited by 377